The world's oceans represent a vast and largely untapped source of biodiversity, offering a high probability for the ...

Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...

(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...

The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...

Kura Oncology and Kyowa Kirin reported positive Phase 1 results for oral menin inhibitor ziftomenib in acute myeloid leukemia ...

Kura Oncology (KURA) and Kyowa Kirin provided encouraging clinical data from KOMET-007, a Phase 1 dose-escalation trial of ziftomenib, a highly ...

Kura Oncology, Inc. (Nasdaq: KURA, "Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin”) provided encouraging cli ...

Triplet induction with alternating consolidation regimens appeared to be effective in patients with newly diagnosed AML, according to researchers.

NCI will include the multi-kinase inhibitor in the umbrella trial evaluating targeted therapy combinations in AML and MDS patients.

Phase 2 data show about half of patients with high-risk or secondary acute myeloid leukemia achieved a complete response or ...